EMAIL THIS PAGE TO A FRIEND

The European journal of neuroscience

IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.


PMID 24649933

Abstract

Ischemic stroke is currently treated with thrombolytic therapy with a drawback to induce hemorrhagic transformation (HT) if applied beyond its relatively narrow treatment time window. The present study was designed to examine the role of IMM-H004, a derivative of coumarin, in recombinant tissue plasminogen activator (tPA)-induced HT. Rats subjected to 6 h of thromboembolic occlusion or middle cerebral artery occlusion received tPA with or without IMM-H004. Delayed tPA intervention drastically increased the risk of HT and exaggerated the ischemic injury. To assess the effect of IMM-H004 on delayed treatment of tPA-induced toxicity after ischemia and reperfusion, various approaches were used, including a behavior test, TTC-staining, determination of cerebral hemorrhage, laser speckle imaging, Western blot, gelatin zymogram, immunohistochemistry and immunofluorescence staining. Experiments were also conducted in vitro in human brain microvascular endothelial cells (HBMECs) and PC12 cells to explore the mechanism for the role of IMM-H004. Combination therapy of tPA and IMM-H004 prevented the development of HT, and reduced the mortality rate, infarct volume and brain edema. IMM-H004 also exerted a protective role by decreasing matrix metalloproteinases, the co-localization of matrix metalloproteinase-2 with astrocytes and increasing occludin. Experiments in HBMECs and PC12 revealed an elevation in ATP level and a protein kinase A- and PI3K-dependent activation of Akt by IMM-H004 after tPA administration. These results suggest IMM-H004 as a promising adjuvant to alleviate the detrimental side effects of tPA in clinical therapy of ischemic stroke, and contribute to better understand the mechanism for the beneficial role of this novel remedy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2100037
Anti-ACTB antibody produced in rabbit, affinity isolated antibody
SAB3500350
Anti-β-Actin antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
M9570 Anti-Matrix Metalloproteinase-9 antibody produced in goat, affinity isolated antibody
HPA001238
Anti-MMP9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
AV33090
Anti-MMP9 antibody produced in rabbit, IgG fraction of antiserum
SAB1406243
Anti-PECAM1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1408616
Anti-PECAM1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
WH0000060M1
Monoclonal Anti-ACTB antibody produced in mouse, clone 3G4-F9, purified immunoglobulin, buffered aqueous solution
SAB1403520
Monoclonal Anti-ACTB antibody produced in mouse, clone 1E7, purified immunoglobulin, buffered aqueous solution
SAB4700463
Monoclonal Anti-CD31 antibody produced in mouse, clone MEM-05, purified immunoglobulin, buffered aqueous solution
AMAB90805
Monoclonal Anti-MMP9 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0539, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90804
Monoclonal Anti-MMP9 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0538, purified immunoglobulin, buffered aqueous glycerol solution
SAB5300247
Monoclonal Anti-MMP9 antibody produced in mouse, clone 5G3, ascites fluid
SAB5300248
Monoclonal Anti-MMP9 antibody produced in mouse, clone 5C3, ascites fluid
AMAB90806
Monoclonal Anti-MMP9 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0542, purified immunoglobulin, buffered aqueous glycerol solution
SAB1402274
Monoclonal Anti-MMP9 antibody produced in mouse, clone 2H4, purified immunoglobulin, buffered aqueous solution
WH0005175M1
Monoclonal Anti-PECAM1 antibody produced in mouse, clone 1D2-1A5, purified immunoglobulin, buffered aqueous solution